Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: A randomized, placebo-controlled, cross-over trial

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 6, 2005, Pages 3295-3303

  Van Thiel, Sjoerd W ^a   Romijn, Johannes A ^a   Pereira, Alberto M ^a   Biermasz, Nienke R ^a   Roelfsema, Ferdinand ^a   Van Hemert, Albert ^b   Ballieux, Bart ^a   Smit, Johannes W A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PARNASSIA PSYCHIATRIC INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; PLACEBO; PRASTERONE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; TESTOSTERONE; ANDROSTANOLONE;

ADRENAL INSUFFICIENCY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN DEFICIENCY; CROSSOVER PROCEDURE; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTROGEN DEFICIENCY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MALE; PARAMETER; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ANXIETY; DEPRESSION; FATIGUE; METABOLISM; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; SEXUAL BEHAVIOR;

ADRENAL INSUFFICIENCY; ADULT; ANXIETY; CROSS-OVER STUDIES; DEPRESSION; DIHYDROTESTOSTERONE; FATIGUE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; PLACEBOS; QUALITY OF LIFE; QUESTIONNAIRES; SEXUAL BEHAVIOR;

EID: 21244493249     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1802     Document Type: Article

References (38)

1. McGauley G 2000 The psychological consequences and quality of life in adults with growth hormone deficiency. Growth Horm IGF Res 10(Suppl B):S63-S68
2. Deijen JB, van der Veen EA 1999 The influence of growth hormone (GH) deficiency and GH replacement on quality of life in GH-deficient patients. J Endocrinol Invest 22(Suppl 5):127-136
3. Hull KL, Harvey S 2003 Growth hormone therapy and Quality of Life: possibilities, pitfalls and mechanisms. J Endocrinol 179:311-333
4. Gilchrist FJ, Murray RD, Shalet SM 2002 The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clin Endocrinol (Oxf) 57:363-370
5. Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC, Lockhart S, Brunand KG, Salomon F, Sonksen PH, Russell-Jones D 1999 The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 84:2596-2602
6. Wiren L, Bengtsson BA, Johannsson G 1998 Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clin Endocrinol (Oxf) 48:613-620
7. Rosilio M, Blum WF, Edwards DJ, Shavrikova EP, Valle D, Lamberts SW, Erfurth EM, Webb SM, Ross RJ, Chihara K, Henrich G, Herschbach P, Attanasio AF 2004 Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab 89:1684-1693
8. Malik IA, Foy P, Wallymahmed M, Wilding JP, MacFarlane IA 2003 Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects. Clin Endocrinol (Oxf) 59:75-81
9. Isidori AM, Kaltsas GA, Perry L, Burrin JM, Besser GM, Monson JP 2003 The effect of growth hormone replacement therapy on adrenal androgen secretion in adult onset hypopituitarism. Clin Endocrinol (Oxf) 58:601-611
10. Aimaretti G, Baffoni C, Ambrosio MR, Maccario M, Corneli G, Bellone S, Gasperi M, Degli Uberti E, Ghigo E 2000 DHEA-S levels in hypopituitaric patients with severe GH deficiency are strongly reduced across lifespan. Comparison with IGF-I levels before and during rhGH replacement. J Endocrinol Invest 23:5-11
11. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM, Allolio B 1999 Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 341:1013-1020
12. Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA, Herbert J, Chatterjee VK 2000 Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab 85:4650-4656
13. Johannsson G, Burman P, Wiren L, Engstrom BE, Nilsson AG, Ottosson M, Jonsson B, Bengtsson BA, Karlsson FA 2002 Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab 87:2046-2052
14. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS 1998 The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 49:421-432
15. Morales AJ, Nolan JJ, Nelson JC, Yen SS 1994 Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78:1360-1367
16. Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, Faucounau V, Girard L, Hervey MP, Latour F, Leaud MC, Mokrane A, Pitti-Ferrandi H, Trivalle C, de Lacharriere O, Nouveau S, Rakoto-Arison B, Souberbielle JC, Raison J, Le Bouc Y, Raynaud A, Girerd X, Forette F 2000 Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 97:4279-4284
17. Villareal DT, Holloszy JO, Kohrt WM 2000 Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol (Oxf) 53:561-568
18. Kawano H, Yasue H, Kitagawa A, Hirai H, Yoshida T, Soejima H, Miyamoto S, Nakano M, Ogawa H 2003 Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 88:3190-3195
19. Genazzani AD, Stomati M, Strucchi C, Puccetti S, Luisi S, Genazzani AR 2001 Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. Fertil Steril 76:241-248
20. Genazzani AD, Stomati M, Bernardi F, Pieri M, Rovati L, Genazzani AR 2003 Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril 80:1495-1501
21. Christiansen JJ, Gravholt C, Fisker S, Svenstrup B, Bennett P, Veldhuis J, Andersen M, Christiansen S, Jorgenson JO 2004 Dehydroepiandrosterone supplementation in women with adrenal failure: impact on twenty-four hour GH secretion and IGF-related parameters. Clin Endocrinol (Oxf) 60:461-469
22. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake L 1992 Validating the SF-36 health survey questionnaire: new outcome measure for primary care. Br Med J 305:160-164
23. Van der Zee KI, Sanderman R 1992 The measument of the general health with the RAND-36, a handbook. Groningen: Rijks Universiteit Groningen, Noordelijk Centrum voor Gezondsheidsvraagstukken
24. McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L, Wiren L 1999 The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 8:373-383
25. Smets EM, Garssen B, Bonke B, De Haes JC 1995 The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39:315-325
26. Smets EM, Visser MR, Willems-Groot AF, Garssen B, Schuster-Uitterhoeve AL, De Haes JC 1998 Fatigue and radiotherapy: (B) experience in patients 9 months following treatment. Br J Cancer 78:907-912
27. Zigmond AS, Snaith RP 1983 The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370
28. Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM 1997 A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 27:363-370
29. De Waal MWM, Arnold IA, Eekhof JAH, Van Hemert AM 2004 Somatoform disorders in general practice: prevalence, functional impairment and co-morbidity with anxiety and depressive disorders according to DSM IV. Br J Psychiatry 184:470-476
30. Hills M, Armitage P 1979 The two-period cross-over clinical trial. Br J Clin Pharmacol 8:7-20
31. Lovas K, Gebre-Medhin G, Trovik TS, Fougner KJ, Uhlving S, Nedrebo BG, Myking OL, Kampe O, Husebye ES 2003 Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J Clin Endocrinol Metab 88:1112-1118
32. Arlt W, Allolio B 2003 DHEA replacement in adrenal insufficiency. J Clin Endocrinol Metab 88:4001-4002
33. Arlt W, Callies F, Allolio B 2000 DHEA replacement in women with adrenal insufficiency: pharmacokinetics, bioconversion and clinical effects on wellbeing, sexuality and cognition. Endocr Res 26:505-511
34. Span JPT, Pieters GFFM, Sweep CGJ, Hermus ARMM, Smals AGH 2000 Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. J Clin Endocrinol Metab 85:1121-1125
35. Hobbs CJ, Plymate SR, Rosen CJ, Adler RA 1993 Testosterone administration increases insulin-like growth factor-I levels in normal men. J Clin Endocrinol Metab 77:776-779
36. Weissberger AJ, Ho KK 1993 Activation of the somatotropic axis by testosterone in adult males: evidence for the role of aromatization. J Clin Endocrinol Metab 76:1407-1412
37. Ip TP, Hoffman DM, O'Sullivan AJ, Leung KC, Ho KK 1995 Do androgens regulate growth hormone-binding protein in adult man? J Clin Endocrinol Metab 80:1278-1282
38. Romijn JA, Smit JW, Lamberts SW 2003 Intrinsic imperfections of endocrine replacement therapy. Eur J Endocrinol 149:91-97